Results 221 to 230 of about 12,578,048 (280)
Impact of Inherited Thrombophilia on Pregnancy Complications and the Role of Low-Molecular-Weight Heparin Therapy: A Case-Control Study. [PDF]
Medicina (Kaunas)Maglic D +5 more
europepmc +1 more source
Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a systematic review of efficacy, safety, and cost-effectiveness. [PDF]
Front PharmacolLi B, Zhao L.
europepmc +1 more source
Low-molecular-weight heparin vs aspirin postpartum (LEAP): a single-center pilot randomized control trial. [PDF]
Blood Vessel Thromb HemostVlachodimitropoulou E +4 more
europepmc +1 more source
Short-term outcomes of unfractionated heparin vs. low molecular weight heparin in trans-radial coronary angiography: a comparative study. [PDF]
Front Cardiovasc MedTaha S +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Heparin and low-molecular-weight heparin
Thrombosis and Haemostasis, 2008SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration.
Elaine Gray +2 more
exaly +3 more sources
Expert Opinion on Pharmacotherapy, 2000
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Current Opinion in Cardiology, 1994
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides
Clinics in Geriatric Medicine, 2006Elderly patients require special consideration when administered anticoagulants because of age-related alterations in renal function, protein binding, and increased bleeding risk. Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation.
Danya L, Dinwoodey, Jack E, Ansell
openaire +2 more sources
Pharmacokinetics of Heparin and Low Molecular Weight Heparins
Haemostasis, 2009The main kinetic features of heparin and low molecular weight heparins (LMWHs) are reviewed. The complexities related to the study of a nonhomogeneous drug containing fractions with different molecular weight and pharmacological effects are discussed along with the possible bias due to the prevalent use of indirect measures of drug concentration ...
E, Ambrosioni, E, Strocchi
openaire +2 more sources